Area of research
Hematology · Oncology
Research interest
Research interests include CD28, Durvalumab, PARP inhibitor, Olaparib, Ovarian cancer, and Medicine.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma